See more : HelloFresh SE (HELFY) Income Statement Analysis – Financial Results
Complete financial analysis of Biodesix, Inc. (BDSX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biodesix, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Munters Group AB (publ) (MMNNF) Income Statement Analysis – Financial Results
- Bunge Limited (BGEPF) Income Statement Analysis – Financial Results
- DT Midstream, Inc. (DTM) Income Statement Analysis – Financial Results
- Shanghai No.1 Pharmacy Co., Ltd. (600833.SS) Income Statement Analysis – Financial Results
- Piala Inc. (7044.T) Income Statement Analysis – Financial Results
Biodesix, Inc. (BDSX)
About Biodesix, Inc.
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 49.09M | 38.21M | 54.51M | 45.56M | 24.55M | 20.43M |
| Cost of Revenue | 13.01M | 14.15M | 30.52M | 22.00M | 6.07M | 4.41M |
| Gross Profit | 36.08M | 24.06M | 23.99M | 23.56M | 18.48M | 16.03M |
| Gross Profit Ratio | 73.50% | 62.96% | 44.01% | 51.71% | 75.26% | 78.44% |
| Research & Development | 9.99M | 13.10M | 12.79M | 10.82M | 10.47M | 8.19M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 30.64M | 25.90M |
| Selling & Marketing | 0.00 | 61.46M | 50.52M | 34.86M | 30.64M | 25.90M |
| SG&A | 67.39M | 61.46M | 50.52M | 34.86M | 30.64M | 25.90M |
| Other Expenses | 44.00K | 109.00K | -9.00K | 422.00K | -2.38M | -1.24M |
| Operating Expenses | 77.42M | 74.56M | 63.31M | 45.68M | 41.11M | 34.09M |
| Cost & Expenses | 90.43M | 88.72M | 93.82M | 67.67M | 47.18M | 38.49M |
| Interest Income | 0.00 | 8.07M | 4.51M | 18.00K | 55.00K | 24.00K |
| Interest Expense | 9.54M | 8.07M | 4.51M | 7.60M | 3.01M | 2.92M |
| Depreciation & Amortization | 5.51M | 3.60M | 3.18M | 2.90M | 2.79M | 1.74M |
| EBITDA | -37.10M | -53.78M | -35.47M | -20.84M | -24.93M | -21.51M |
| EBITDA Ratio | -75.59% | -131.89% | -72.15% | -47.58% | -90.25% | -85.81% |
| Operating Income | -41.34M | -50.51M | -39.32M | -22.12M | -22.63M | -23.46M |
| Operating Income Ratio | -84.22% | -132.17% | -72.14% | -48.55% | -92.16% | -114.82% |
| Total Other Income/Expenses | -10.80M | -14.86M | -2.22M | -8.42M | -3.99M | -2.71M |
| Income Before Tax | -52.15M | -65.45M | -43.16M | -31.35M | -30.73M | -26.17M |
| Income Before Tax Ratio | -106.23% | -171.27% | -79.18% | -68.81% | -125.15% | -128.06% |
| Income Tax Expense | 0.00 | 14.94M | 1.32M | 5.12M | 629.00K | 211.00K |
| Net Income | -52.15M | -80.39M | -44.48M | -36.47M | -31.36M | -26.17M |
| Net Income Ratio | -106.23% | -210.37% | -81.61% | -80.06% | -127.71% | -128.06% |
| EPS | -0.64 | -1.91 | -1.63 | -1.37 | -1.23 | -0.99 |
| EPS Diluted | -0.64 | -1.91 | -1.63 | -1.37 | -1.23 | -0.99 |
| Weighted Avg Shares Out | 82.11M | 42.10M | 27.37M | 26.56M | 25.49M | 26.54M |
| Weighted Avg Shares Out (Dil) | 82.11M | 42.10M | 27.37M | 26.56M | 25.49M | 26.54M |
Biodesix to Report Third Quarter 2023 Financial Results on November 7, 2023
Biodesix to Present New Data on Nodify Lung® Testing at CHEST 2023 Annual Meeting
Why You Should Bet on 4 Top-Ranked Stocks With Rising P/E
Biodesix Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer
Biodesix to Participate in Two Upcoming Investor Conferences in September
Biodesix Announces Presentation of New Nodify XL2® Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer
Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates
Biodesix, Inc. (BDSX) Q2 2023 Earnings Call Transcript
Biodesix Announces Second Quarter 2023 Results and Highlights
Biodesix to Participate in the Canaccord Genuity 43rd Annual Growth Conference
Source: https://incomestatements.info
Category: Stock Reports